Altamira Therapeutics Ltd. balance sheet CYTOF

Annual Quarterly

As of Dec 31, 2024, Altamira Therapeutics Ltd. had total assets of $8.7 million and total liabilities of $2.1 million. Stockholders' equity was $6.6 million. It held $998,624 in cash and investments against $361,053 of total debt, net cash of $637,571. The current ratio, current assets divided by current liabilities, was 1.32.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2024
Dec 31, 2024
Assets
Cash
1
Cash and investments
1
Total current assets
2
Property and equipment, net
0
Total assets
9
Liabilities and equity
Accounts payable
1
Total current liabilities
1
Total liabilities
2
Stockholders' equity
7
Debt
Lease liabilities
0
Total debt
0
Net cash
1
Ratios
Current ratio
1.32x
Debt to equity
0.05x
Return on equity
-128.83%
Return on assets
-97.75%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CYTOF (OTC)
Fiscal year ends
December 31
Incorporated in
Bermuda
Headquarters
Hamilton Hm 11, Bermuda
SEC filer status
Non-accelerated filer
SEC CIK
1601936
Former names
Auris Medical Holding Ltd. (until Jul 23, 2021); Auris Medical Holding AG (until Mar 14, 2019); Auris Medical AG (until Apr 18, 2014)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.